COSMOS: CytOSorb TreatMent Of Critically Ill PatientS Registry

Sponsor

CytoSorbents, Inc (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05146336

Collaborator

(none)

3,000

Enrollment

Locations

107.3

Anticipated Duration (Months)

1500

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

Condition or Disease	Intervention/Treatment	Phase
Critical Illness Septic Shock Vasogenic Shock Acute Respiratory Distress Syndrome Severe Acute Respiratory Syndrome Liver Failure Trauma Rhabdomyolysis Corona Virus Infection Vasoplegic Syndrome Cardiogenic Shock Pancreatitis	Device: CytoSorb

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

3000 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting

Actual Study Start Date :

Jun 22, 2022

Anticipated Primary Completion Date :

Mar 1, 2031

Anticipated Study Completion Date :

Jun 1, 2031

Outcome Measures

Primary Outcome Measures

ICU mortality [Through ICU discharge or date of death, whichever comes first [on average 7 days]]
In-hospital mortality [Through hospital discharge or date of death, whichever comes first [on average 14 days]]